9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques
about
Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strainsAntiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in micePrevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovirBiological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesEarly short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatmentProphylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatmentActivated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj.Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPAPhase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Nonhuman primate models for HIV cure research.Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251.Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaquesClinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissueSequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes.Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.Tenofovir resistance and resensitizationHighly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent diseasePharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques.CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy.Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonatesTenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
P2860
Q28379552-08BC84AA-B0DC-4FA9-85E4-B87EDFC6BD96Q28379614-B2421AD2-3CA2-4C95-BC94-CB2CEEF50407Q28472146-E614F43A-ADA3-4BC8-9B98-5EC65E10C5C2Q28775900-7CF607AA-BF56-4764-B297-23AAF8F8CD06Q33643898-654C9BCD-DF7D-48BA-9D81-A3AED8162D31Q33653655-39A94D29-B380-44C0-A232-3C12B56C05F4Q33697044-534AF242-FD6B-4D80-9710-61DDFD0F6C1CQ33782843-9EDC791A-6464-4A1E-8BA0-ED9F8DAC28B8Q33797464-5B7AA3A8-71DD-4BF9-B7A5-EC9959BEF09FQ33799700-08D51DA6-AC4B-41C5-9001-B7AA30AB8C5CQ33817369-184DA018-7D9A-40FA-B1A1-5F13DCD0412CQ33820791-1D6E048A-673A-4534-AAD0-6D9569C36004Q33966329-DC205668-E3A5-41A6-95CA-57756CADB9B6Q33976617-ACAC4A96-076C-452E-BEAC-5838C602E901Q33983070-450BE365-76F6-4538-9509-174536F8E19DQ34339657-9FF1E518-DD90-4FB9-BFC5-ED582A70A111Q34407781-03719CC3-8ED3-4A30-A50D-CA866BDCDFDBQ34462107-E7E49516-05F3-4F2E-99D2-20E8D4D60E25Q34465037-A6214997-5498-4D95-84F9-8FD4E984FE99Q34716901-84705C9B-E8EB-46E9-85FD-485CE8CCC941Q35024276-70D00ED6-D43E-4C13-A2BB-CB2D58734EB4Q35132138-9CBBD7AD-4885-4E3C-B1DF-1F7053EF89A6Q35558801-E122ECD3-52B8-49D9-8DF6-9473840D3280Q35665851-BC17ED75-8610-4098-973B-CB426CBF252BQ35752812-475F5D60-D2CC-463B-A3B9-231D79BDCDB7Q36164175-53C74FE3-B697-4D71-92E2-A0E28D9DE24CQ36389032-E706F6D1-FBF0-4B36-8093-CBD18416E0CEQ36473475-99F787C2-4DAE-464D-9173-72D7341D3AF3Q36870864-1A588560-F66D-47CE-A3BB-F64190990326Q36879987-94E436A5-ADDC-461B-A390-07C808000838Q36954674-D26D19EE-5F03-4684-B621-B1B70DB7CFB7Q37248025-45A299A7-A868-4274-925A-DCE1E326527AQ37713043-8692DEA2-E80D-4B42-8564-3AFDD579DA17Q37730097-10A876EC-B9CC-4664-BBAD-0D3ED51C93D1Q37780687-2C89AFF0-CA67-4062-8A1C-8AE633A3F320Q39651462-9503CD26-7DFA-42BD-9977-31FB693FA09AQ39652313-1155EC66-C007-4988-915B-2A60F50B57F9Q43011767-100C3914-2D76-4363-AE99-1DF192C7EB6A
P2860
9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
name
9-[2-(Phosphonomethoxy)propyl] ...... tion in infant rhesus macaques
@ast
9-[2-(Phosphonomethoxy)propyl] ...... tion in infant rhesus macaques
@en
type
label
9-[2-(Phosphonomethoxy)propyl] ...... tion in infant rhesus macaques
@ast
9-[2-(Phosphonomethoxy)propyl] ...... tion in infant rhesus macaques
@en
prefLabel
9-[2-(Phosphonomethoxy)propyl] ...... tion in infant rhesus macaques
@ast
9-[2-(Phosphonomethoxy)propyl] ...... tion in infant rhesus macaques
@en
P2093
P2860
P1476
9-[2-(Phosphonomethoxy)propyl] ...... tion in infant rhesus macaques
@en
P2093
A S Mulato
C J Berardi
D R Canfield
J M Cherrington
K K Van Rompay
M L Marthas
N Bischofberger
N C Pedersen
R P Tarara
P2860
P304
P407
P577
1996-11-01T00:00:00Z